Building well-being means the world to us
Discover more
Interim report January-March 2026
Orion published Interim Report for January–March 2026 on Thursday, 23 April 2026.
Read the report
Stock exchange releases
- 4/23/2026 Orion Group Interim report January–March 2026
- 4/1/2026 Change in Orion Group Executive Team as of 8 April 2026 – Berkeley Vincent appointed Executive Vice President, Innovative Medicines
- 3/24/2026 Decisions taken by Orion Corporation's Annual General Meeting and Board of Directors' organising meeting on 24 March 2026
- 3/10/2026 Orion Corporation: Transfer of 172,778 own B shares on 10 March 2026
Press releases
- 4/23/2026 Orion Pharma initiates TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard of care treatments in patients with select advanced solid tumours
- 4/20/2026 Orion Pharma’s ODM-212 Granted Orphan Drug Designation in Mesothelioma by the US FDA
- 4/10/2026 Orion publishes Interim Report for January–March 2026 and holds a webcast on 23 April 2026
- 3/18/2026 Peace through well-being: Orion and CMI - Martti Ahtisaari Peace Foundation announce partnership